Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Opiant Pharmaceuticals, Inc. (OTC: OPNT).

Full DD Report for OPNT

You must become a subscriber to view this report.


Recent News from (OTC: OPNT)

Senate vote approaches on bill to combat opioid crisis
The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news...
Source: SeekingAlpha
Date: September, 07 2018 12:48
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa
Top-line Results Expected in First Quarter of 2019 SANTA MONICA, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) --  Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug ove...
Source: GlobeNewswire
Date: September, 04 2018 08:00
Today's Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio
NEW YORK, NY / ACCESSWIRE / August 30, 2018 / Shares of Opiant saw big gains after Wall Street learned that Emergent Biosciences Inc. announced the acquisition of Adapt Pharma® for $635 million. Adapt markets NARCAN® Nasal Spray for the treatment of opioid overdose, for which Opia...
Source: ACCESSWIRE IA
Date: August, 30 2018 08:00
Midday Gainers / Losers (08/29/2018)
Gainers: OPNT +50% . IGC +40% . GKOS +36% . EVFM +26% . IPAS +27% . SPHS +27% . AFMD +25% . JMU +19% . YRD +17% . ZYNE +17% . More news on: Opiant Pharmaceuticals, Inc., India Globalization Capital, Inc, Glaukos, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 29 2018 12:48
FDA updates on multifaceted plan to combat opioid crisis
In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 29 2018 12:44
Premarket Gainers as of 9:05 am (08/29/2018)
OPNT +79%  on EBS takeout of Adapt Pharma. More news on: Opiant Pharmaceuticals, Inc., Glaukos, India Globalization Capital, Inc, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 29 2018 09:24
Opiant Pharma up 73% premarket on EBS takeout of Adapt Pharma
Thinly traded nano cap Opiant Pharmaceuticals (NASDAQ: OPNT ) is up  73%  premarket on increased volume on the heels of Emergent BioSolutions' announced acquisition of Adapt Pharma for up to $735M. More news on: Opiant Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
Source: SeekingAlpha
Date: August, 29 2018 08:44
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals, Inc. and Opiant Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / August 29, 2018 / U.S. equities rallied on Tuesday as consumer confidence hits an eighteen-year high and optimism over new proposed trade agreement between U.S. and Mexico continue to push broader markets higher. Consumer confidence increased from 127.9 in July t...
Source: ACCESSWIRE IA
Date: August, 29 2018 08:00
FDA clamps down on opioid-peddling websites
The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc...
Source: SeekingAlpha
Date: August, 28 2018 10:57
FDA awards contract to develop guidelines for opioid prescribing
The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND...
Source: SeekingAlpha
Date: August, 22 2018 11:16

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1216.0016.0016.0015.3114,038
2018-12-1116.0015.9016.0015.305,977
2018-12-1015.7615.9615.9915.386614,856
2018-12-0715.8615.9316.0015.65125,025
2018-12-0616.1016.0016.2915.386614,748

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2017-08-2817,47724,52971.2504Short
2017-08-2514,66233,14544.2359Short
2017-08-243,80510,18637.3552Short
2017-08-236,90313,05952.8601Short
2017-08-2211,18816,01469.8639Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on OPNT.


About Opiant Pharmaceuticals, Inc. (OTC: OPNT)

Logo for Opiant Pharmaceuticals, Inc. (OTC: OPNT)

Opiant Pharmaceuticals is a specialty pharmaceutical company developing treatments for substance use, addictive and eating disorders.

 

 

 

Current Management

  • Roger Crystal / CEO, President
  • Kevin Pollack / CFO, Treasurer, Secretary
  • Michael Sinclair / Chairman, Executive Chairman
  • Roger Crystal /
  • Ann MacDougall / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Kevin Pollack /
  • Gabrielle Silver / Independent Director, Nominating Committee Member
  • Thomas T. Thomas / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Geoffrey Wolf / Independent Director, Audit Committee Member, Nominating Committee Member

Current Share Structure

  • Market Cap: $51,491,272 - 03/09/2018
  • Authorized: 200,000,000 - 03/01/2018
  • Issue and Outstanding: 2,537,766 - 03/01/2018

 


Recent Filings from (OTC: OPNT)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 18 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 17 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 17 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: April, 11 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 19 2018
Annual transition reports filed under rule 13a-10 or 15d-10 of the Securities Exchange Act
Filing Type: 10-KTFiling Source: edgar
Filing Date: March, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 05 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: February, 28 2018

 

 


Daily Technical Chart for (OTC: OPNT)

Daily Technical Chart for (OTC: OPNT)


Stay tuned for daily updates and more on (OTC: OPNT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: OPNT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in OPNT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of OPNT and does not buy, sell, or trade any shares of OPNT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/